期刊文献+

ERK1/2在左旋多巴诱导的异动症发生机制中的作用

The Role of ERK1/2 in the pathogenesis of levodopa induced dyskinesia
原文传递
导出
摘要 目的研究细胞外调节激酶(ERK1/2)在左旋多巴诱导的异动症(LID)发生机制中的作用。方法将SD大鼠分为5组:正常对照组、帕金森病(PD)组、LID组、LID+SCH23390组和非LID组,分别观察各组行为学变化,并用免疫组化方法测定大鼠纹状体区ERK1/2及其活化形式p-ERK1/2表达水平。结果多巴胺D1受体阻断剂SCH23390可以减轻LID大鼠行为学异常;LID组和非LID组ERK1/2的表达无显著性差异,而LID组p-ERK1/2的表达较非LID组和PD组明显增加,SCH23390使其表达下降。结论ERKI/2是LID大鼠纹状体内直接输出通路上的重要信号分子,其活化参与了异动症的发生。 Objective To study the role of extracellular regulated kinase 1/2(ERK1/2) and phosphorylated-ERK1/2(p-ERK1/2) in the molecular pathogenesis of LID(L-EK)PA induced dyskinesia). Methods All rats were divided into five groups: normal control group, PD group, LID group, LID + SCH23390 group and non-LID group. The behavioral changes were observed. The expression of ERK1/2 and p-ERK1/2 in striatum were measured and compared in each groups using immuno-histochemistry. Results Dopamine D1 receptor antagonist SCH23390 attenuated abnormal behavior of LID rats. ERK1/2 expression in LID rats was equal to non-LID group. LID rats expressed more p-ERKI/2 than PD rats and non-LID rats,which could be reduced by SCH23390. Conclusions ERK1/2 was an important signal cascade molecules in direct output pathway of striaturn in IAD rat, and its activity may be involved in pathogenesis of LID.
出处 《卒中与神经疾病》 2008年第3期156-159,163,共5页 Stroke and Nervous Diseases
基金 国家自然科学基金项目(No30300114)
关键词 左旋多巴 异动症 ERK1/2多 巴胺D1受体 Levodopa dyskinesia ERK1/2 Dopamine D1 receptor
  • 相关文献

参考文献14

  • 1Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease:an update. Clin Pharmaeokinet, 2006,45 (2) : 109-136.
  • 2管强,曹学兵,孙圣刚,徐岩.帕金森病及异动症大鼠模型纹状体神经元的电生理变化的研究[J].卒中与神经疾病,2005,12(6):323-325. 被引量:4
  • 3Valjent E,Caboche J, Vanhoutte P. Mitogen-activated protein kinase/extracellular signal-regulated kinase induced gene regulation in brain: a molecular substrate for learning and memory? Mol Neurobiol, 2001,23 (2-3) : 83-99.
  • 4Thomas J,Wang J, Takuba H, et al. A 6-OHDA induced selective Parkinsonian rat model: further biochemical and behavioural characterization. Exp Neurol, 1994,126 (2) : 159-167.
  • 5Lundblad M, Andersson M, Winkler C, et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci, 2002, 15 ( 1 ) : 120-132.
  • 6徐岩,孙圣刚,曹学兵.左旋多巴诱发异动症大鼠模型的制作及其行为学评估[J].中华物理医学与康复杂志,2005,27(11):649-652. 被引量:15
  • 7Lee CS, Cenci MA, Sehulzer M, et al. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson disease. Brain,2000,123(7):1365-1379.
  • 8Pavon N,Martin AB, Mendialdua A,et al. ERK Phosphorylation and FosB Expression Are Associated with L-DOPA-Induced Dyskinesia in Hemiparkinsonian Mice. Biol Psychiatry, 2006, 59 (1):64-74.
  • 9Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord, 2005,20 (8):919-931.
  • 10Charles R. Gerfen, Shigehiro Miyachi and Ronald Paletzki, D1 Dopamine Receptor Supersensitivity in the Dopamine-Depleted Striatum Results from a Switch in the Regulation of ERK1/2/ MAP Kinase. J Neurosci,2002,22(12) :5042-5054.

二级参考文献16

  • 1Thomas J,Wang J,Takuba H,et al.A 6-OHDA induced selective Parkinsonian rat model:further biochemical and behavioural characterization.Exp Neurol,1994,126:159-167.
  • 2Chang JW,Wachtel SR,Yong D,et al.Biochemical and anatomical cha-racterization of forepaw adjusting steps in rat models of Parkinson's di-sease:studies on medial forebrain bundle and striatal lesions.Neurosci,1999, 88: 617-628.
  • 3Lee CS,Cenci MA,Schulzer M,et al.Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.Brain,2000,123:1365-1379.
  • 4Nutt JG.Levodopa-induced dyskinesia:review,observation and speculations.Neurology,1990,40:340-345.
  • 5Westin JE,Andersson M,Lundblad M,et al.Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease.Eur J Neurosci,2001,14:1171-1176.
  • 6Johansson PA,Andersson M,Andersson KE,et al.Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of L-DOPA-induced dyskinesia.Neurobiol Dis,2001,8:220-239.
  • 7Lundblad M,Andersson M,Winkler C,et al.Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.Eur J Neurosci,2002,15:120-132.
  • 8Westin JE,Andersson M,Lundblad M,et al.Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease. Eur J Neurosci,2001,14:1171-1176.
  • 9Blanchet PJ,Calon F,Morissette M,et al.Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms.Parkinsonism Relat Disord,2004,10(5):297-304.
  • 10Thomas J,Wang J,Takuba H,et al.A 6-OHDA induced selective Parkinsonian rat model:further biochemical and behavioural characterization.J Exp Neurol,1994,126(2):159-161.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部